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upon methyl donor repletion in UD-SCC2 cells. In addi-
tion, expression of DAPK1 and PUMA was increased in 
UD-SCC2 cells cultured in methyl donor deplete compared 
to complete medium, possibly explaining the observed 
increase in apoptosis in these cells.
Conclusion Taken together, these data show that deplet-
ing HNSCC cells of methyl donors reduces the growth and 
mobility of HNSCC cells, while increasing rates of apopto-
sis, suggesting that a methyl donor depleted diet may sig-
nificantly affect the growth of established HNSCC.
Keywords DNA methylation · Head and neck cancer · 
Methyl donor · Apoptosis · DAPK
Introduction
It is estimated that there were 140,000 new cases and 
63,500 deaths from head and neck squamous cell carci-
noma (HNSCC) in Europe in 2012 [1]. The 5-year age-
standardised relative survival rate was approximately 40% 
for Europe overall with survival rates lowest in Eastern 
European and highest in Central, Western, and Northern 
European counties for all sub-categories of HNSCC such 
as oral cavity, oropharyngeal, laryngeal, and hypopharyn-
geal cancer [2]. Head and neck squamous cell carcinoma 
(HNSCC) is frequently (54%) detected at an advanced 
stage and so often has a poor prognosis with less than 55% 
overall 5-year survival following diagnosis [2, 3]. HPV 
infection is responsible for virtually all cervical cancers and 
approximately 35% of diagnosed oropharyngeal cancers 
worldwide, although there is a significant region to region 
variation globally [4]. Chaturvedi et  al. predict that the 
number of HPV-positive HNSCC cases will exceed cases 
of cervical cancer by 2020, demonstrating the urgent need 
Abstract 
Purpose DNA methylation plays a fundamental role in 
the epigenetic control of carcinogenesis and is, in part, 
influenced by the availability of methyl donors obtained 
from the diet. In this study, we developed an in-vitro model 
to investigate whether methyl donor depletion affects the 
phenotype and gene expression in head and neck squamous 
cell carcinoma (HNSCC) cells.
Methods HNSCC cell lines (UD-SCC2 and UPCI-
SCC72) were cultured in medium deficient in methionine, 
folate, and choline or methyl donor complete medium. 
Cell doubling-time, proliferation, migration, and apoptosis 
were analysed. The effects of methyl donor depletion on 
enzymes controlling DNA methylation and the pro-apop-
totic factors death-associated protein kinase-1 (DAPK1) 
and p53 upregulated modulator of apoptosis (PUMA) were 
examined by quantitative-PCR or immunoblotting.
Results HNSCC cells cultured in methyl donor deplete 
conditions showed significantly increased cell doubling 
times, reduced cell proliferation, impaired cell migra-
tion, and a dose-dependent increase in apoptosis when 
compared to cells cultured in complete medium. Methyl 
donor depletion significantly increased the gene expres-
sion of DNMT3a and TET-1, an effect that was reversed 
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for a better understanding of the disease process and poten-
tial prevention strategies [5].
Folate is an essential dietary component required for the 
synthesis of nucleotides and for the synthesis and repair of 
DNA. There are several mechanisms by which folate sta-
tus affects cancer risk. Low folate status has been shown 
to cause uracil mis-incorporation into DNA [6], cytoge-
netic damage [7], and impaired DNA repair [8] all of 
which increase the risk of neoplastic change. Indeed, epi-
demiological studies have shown that low dietary folate 
intake is associated with an increased risk of HNSCC car-
cinogenesis [9–11]. Conversely, other studies have shown 
that a high folate status may drive the growth of estab-
lished tumours [12, 13]. In addition, there is evidence that 
folate status affects HPV infection and behaviour. Studies 
by our group and others have shown that low folate sta-
tus is associated with an increased risk of cervical HPV 
infection [14, 15] and cervical intraepithelial neoplasia or 
invasive cancer [15]. The direction of influence of folate 
status on HPV persistence is not clear [14, 15]. Recently, 
Xiao et  al. showed that low folate conditions increased 
HPV integration into the keratinocyte host genome and 
reduced viral capsid production in human keratinocytes 
in vitro [16]. Folate and other diet-derived methyl donors 
(choline, betaine, methionine) may also influence cancer 
risk and progression through epigenetic effects. The epi-
genetic control of gene expression is regulated, in part, by 
the methylation of cytosine–guanine dinucleotides within 
gene promoter regions, and dysregulated methylation in 
the promoter sequences of tumour-suppressor or oncogenes 
can promote carcinogenesis in HNSCC [17, 18]. For the 
methylation of DNA, methyl groups are transferred from 
the ultimate methyl donor, s-adenosyl methionine (SAM), 
onto cytosine residues in DNA by DNA methyltransferases 
(DNMTs). Whilst the factors that regulate DNMTs are not 
well understood, there is evidence that methyl donor deple-
tion may lower DNMT expression in cervical cancer cells 
enzymes. DNMT1 preferentially adds methyl groups to 
hemi-methylated DNA and is responsible for maintenance 
of DNA methylation following cell division [19]. DNMT3a 
and 3b add methyl groups to CpG sites and are required for 
de novo DNA methylation [20]. In contrast, Tet methyl-
cytosine dioxygenase 1 has been implicated in demethyla-
tion of DNA [21]. Poomipark et al. recently demonstrated 
methyl donor status altered the expression of DNMTs in 
cervical cancer cells [22]. Appropriate gene methylation 
is important for the regulation of many processes, includ-
ing those involved in cancer progression such as cell cycle 
control and apoptosis. In addition, cell stress due to lack of 
essential nutrients may also lead to increased expression of 
key pro-apoptotic genes such as death-associated protein 
kinase-1 (DAPK1) [23] and p53 upregulated modulator of 
apoptosis (PUMA) [24], and so alterations in methyl donor 
availability may have profound effects on cell behaviour.
Here, we have developed an in  vitro model of methyl 
donor-deficient HNSCC cells, with particular emphasis 
on HPV-positive HNSCC. We show, for the first time, that 
methyl donor deficiency significantly alters the pheno-
type of HNSCC cells by decreasing their proliferation and 
migratory capacity whilst up-regulating the expression of 
pro-apoptotic genes and increasing levels of apoptosis.
Materials and methods
Cell culture and methyl donor depletion
UD-SCC2 (HPV-positive) [25] and UPCI-SCC72 (HPV-
negative) [26] cells were cultured in RPMI medium supple-
mented with 10% (v/v) fetal bovine serum (FBS), 100 IU/
ml penicillin, and 100 μg/ml streptomycin (Sigma, Poole, 
UK), and confirmed as HPV-16 positive by qPCR and p16 
staining. In addition to measuring in the HNSCC cell lines 
used in the model, DAPK1 promoter methylation was also 
measured in UPCI-SCC89, UPCI SCC152, UPCI SCC154 
[26], and FaDu [27]; the cervical carcinoma cell lines HeLa 
[28] and SiHa [29]; the oral dysplastic epithelial cell line 
(DOK) [30]; and the basaloid squamous cell carcinoma 
cell line (PE/CA-PJ34, clone C12) [31]. All cells were cul-
tured at 37 °C, 5%  CO2 as per supplier instructions. All cell 
lines were verified using short tandem repeat (STR) analy-
sis (Public Health England). RPMI cell culture medium 
contains methyl donors at the following concentrations: 
l-methionine 101  µmol/L, choline chloride 21.4  µmol/L, 
and folic acid 2.26 µmol/L; this was designated ‘complete 
medium (100%)’. RPMI medium containing no l-methio-
nine, choline chloride, or folic acid (0% methyl donors) was 
custom-made by  Gibco® (customisation of #11875093) and 
then supplemented with 10% (v/v) FBS, 100 IU/mL peni-
cillin, and 100 μg/mL streptomycin. Complete medium and 
0% medium were mixed in appropriate ratios to produce 
media containing increasing amounts of methyl donors 
(e.g., 40, 20, 10, and 5%) of the complete medium. To avoid 
a metabolic shock response to depleted medium, cells were 
gradually depleted of methyl donors over time for 4 days. 
Cells were then cultured in the experimental methyl donor 
concentrations for 4 days prior to seeding the cells for the 
experiments and experiments were performed at the methyl 
donor concentrations as indicated. The concentration of 
methyl donors in FBS is minimal [32]; the same batch of 
FBS was used throughout. For repletion experiments, cells 
were returned to complete culture media (100%) after a 
total of 15 days in depleted conditions and analysed 72 h 
later.
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Measurement of methyl donors
As a marker of disturbance to the methylation cycle, 
extracellular homocysteine was measured using a high-
performance liquid chromatography detection kit (Chrom-
systems, Gräfelfing, Germany). Cell culture medium was 
collected and centrifuged to remove cell debris before 
storage at −80 °C. Homocysteine concentration was nor-
malised to cell number. Intracellular choline, betaine, and 
methionine concentrations were determined using isotope 
dilution liquid chromatography tandem mass spectrometry 
as previously described [33].
RNA extraction and quantitative RT-PCR
Total RNA was isolated (Bioline, London, UK) and 700 ng 
reverse transcribed using High Capacity cDNA Reverse 
Transcription Kit with RNase Inhibitor. Quantitative PCR 
was performed using a 7900HT Fast Real-Time PCR 
System with thermal cycles of 50 °C (2  min) and 95 °C 
(10 min) followed by 40 cycles of 95 °C (15 s) and 60 °C 
(1 min). For DNMT detection the reaction mix consisted of 
300 nM of both forward and reverse primers (Sigma, Poole, 
UK), 125  nM FAM-labelled probe specific to DNMT 1, 
3a and 3b [34], 2X  TaqMan® mastermix, 0.5  µL β-2-
Microglobulin (β2M) reference control with VIC-reporter 
dye, and 35  ng cDNA. Inventoried  TaqMan® FAM-
labelled probes were used to measure expression of DAPK1 
(Hs00234480_m1), TET1 (Hs00286756_m1) and PUMA 
(Hs00248075_m1). β-2-Microglobulin (Hs00984230_m1) 
with a VIC-reporter dye was used as a reference control 
gene. Relative change in gene expression was calculated 
using the  2−ΔΔCt method.
Cell migration
Cell migration was measured using the Oris™ cell migra-
tion assay (Platypus Technologies, Madison USA). Cells 
were seeded into 96-well plates and a circular exclusion 
zone was created using a stopper to prevent cell adherence 
in the centre of the well as per the manufacturer’s guide-
lines. Once adhered, cells were treated with 0.5  µg/mL 
mitomycin C (Sigma, Dorset, UK) for 4  h to inhibit cell 
division, and the stopper was removed to create an exclu-
sion zone of 5.37 ± 0.05  mm2 that was imaged using a 
Spot™ USB camera (Spot Imaging Solutions, Michigan, 
USA) at baseline and following cell migration after 72 h.
Cell counts and cell proliferation
UD-SCC2 and UPCI-SCC72 cells were detached from tis-
sue culture plates at 24, 72, and 168  h after seeding and 
live cells counted on a haemocytometer using trypan blue 
exclusion. Eighteen counts were performed for each con-
dition and each experiment was performed three times. 
Cell doubling time was calculated using Doubling Time 
software (http://www.doubling-time.com). Cell prolifera-
tion was measured using  CellTrace™ CFSE Cell Prolifera-
tion Kit. Cell suspensions (1 × 106  cells/mL) were incu-
bated with 1 µM CSFE  CellTrace™ in PBS/0.1% BSA for 
10  min at 37 °C, quenched in cold media, incubated for 
5 min on ice, washed twice in PBS/0.1% BSA, and seeded 
into 6-well plates. The following day, negative cell controls 
were incubated with mitomycin C (0.5  µg/mL) for 4  h at 
37 °C to prevent cell division. At 72 and 168 h, cells were 
detached, washed, and fixed in 4% paraformaldehyde. Cell 
fluorescence intensity was analysed using a  BD™ LSRII 
flow cytometer (BD Biosciences, Oxford, UK) and the 
proliferation index calculated as fluorescence intensity of 
mitomycin C-treated negative control cells/sample cell flu-
orescence intensity.
Apoptosis
Apoptosis analysis was performed using the TACS Annexin 
V-FITC, Apoptosis Detection Kit, (Trevigen Inc. Gaith-
ersburg, MD, USA). UD-SCC2 and UPCI-SCC72 cells 
were detached, washed, and incubated with FITC-labelled 
Annexin V and propidium iodine immediately prior to anal-
ysis. Cell fluorescence was analysed using a  BD™ LSRII 
flow cytometer (BD Biosciences). Fluorescence gates were 
set at the beginning of the experiment using unlabelled and 
single labelled cells as well as positive controls for necrosis 
(1% saponin) and apoptosis (30%  H2O2 for 10 min) (Sup-
plementary Fig. 1). Cells were considered apoptotic if they 
showed positive staining for Annexin V, necrotic if they 
were positive for propidium iodine but not Annexin V and 
live if negative for both stains.
Immunoblotting of death-associated protein kinase 1 
(DAPK1)
Protein was extracted from cell pellets using ice-cold RIPA 
buffer with protease and phosphatase inhibitors (Roche 
Diagnostics Ltd., Sussex, UK), and protein concentra-
tion calculated using the bicinchoninic acid assay. Twenty 
micrograms of protein were separated using  Novex® 
4–12% Tris–Glycine gels and transferred to a nitrocellulose 
membrane by semi-dry transfer. Membranes were blocked 
with 5% (w/v) BSA in Tris-buffered saline containing 
0.05% (v/v) Tween-20 (TBST), and membranes were then 
incubated with antibodies directed to DAPK1 (clone55; 
1:250 dilution; Sigma Aldrich, Poole, UK) or phosphoryl-
ated DAPK1 (pSer308; 1 µg/mL dilution; Novus Biologi-
cals, Cambridge, UK) overnight at 4 °C or with anti-β-actin 
(1:30,000; Cell Signalling  Technologies®, Danvers, MA) 
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for 1 h at room temperature. Membranes were washed and 
incubated with anti-mouse IgG horseradish peroxidase-
conjugated secondary antibody (1:3000 dilution; Cell Sig-
nalling  Technologies®). All antibodies were diluted in 5% 
BSA/TBST. Immuno-reactive proteins were visualized 
using an enhanced chemiluminescent substrate for detec-
tion of horseradish peroxidase activity  (Pierce™ ECL West-
ern Blotting Substrate, ThermoFisher).
Genomic DNA isolation, bisulfite modification of DNA, 
and quantitative methyl-specific PCR
Genomic DNA was extracted from a panel of cell lines 
 (QIAamp® DNA Mini kit, Qiagen) and 1  µg DNA was 
bisulphite treated using the EZ DNA  Methylation™ kit 
(Zymo Research, Freiburg, Germany). Methyl-specific 
qPCR (qMSP) was performed to determine the presence of 
methylated DAPK1 promoter. The reaction mixture com-
prised of:  TaqMan® Universal Mastermix II no UNG, 250 
nM forward and reverse primers, 250  nM FAM-labelled 
probe with minor groove binding modification [35], and 
500 ng bisulphite-treated DNA. β-actin was used as the ref-
erence control gene and amplified as follows:  1xTaqMan® 
Universal Mastermix II no UNG, 900 nM forward and 
reverse primers, 250  nM VIC-labelled probe, and 100  ng 
bisulphite treated DNA. A fully methylated DNA control 
was used as a positive control (Zymo Research Europe, 
Freiburg, Germany). The following thermal profile was 
performed: 95 °C for 10 min, then 50 cycles of 95 °C (15 s), 
65 °C (5 s), and 62.5 °C (55 s) using a 7900HT Fast Real-
Time PCR System.
Statistical analysis
Statistical analysis was performed using SPSSv.20 (IBM, 
Hampshire, UK) and data are expressed as mean ± standard 
deviation. All data were tested for homogeneity of variance 
using Levene’s prior to parametric statistical analysis. Pair-
wise comparisons were conducted using an Independent 
Student’s unpaired t test (Figs. 1, 2, 3b, 4a) and group-wise 
comparisons were carried out using one-way independent 
ANOVA with Bonferroni post-hoc comparison (Fig. 3c–e). 
Differences were considered significant if p < 0.05.
Results
Establishment and validation of an in vitro model 
of methyl donor depletion
Disturbance to the methyl cycle caused by a deficiency of 
methyl donors is characterised by an increase in homocyst-
eine concentration; this is well documented as an increase 
in plasma homocysteine in human studies [36] and in 
extracellular homocysteine levels in in  vitro studies [37]. 
Figure  1a shows an increase in the extracellular homo-
cysteine of UD-SCC2 after 72  h of growth in 5% methyl 
donor-deficient medium compared with growth in com-
plete medium, and by 168 h, the difference reached statisti-
cal significance (p < 0.05). Unlike the UD-SCC2 cell line, 
the UPCI-SCC72 cells were unable to proliferate and sur-
vive in culture media containing methyl donor concentra-
tions below 20% of standard cell culture concentrations. In 
UPCI-SCC72 cells, an increase in extracellular homocyst-
eine was observed at 72 and 168 h of growth in 20% methyl 
donor medium (Supplementary Fig. 2A). These data con-
firm a functional disturbance to the methyl cycle in both 
UD-SCC2 and UPCI-SCC72 cells, validating the methyl 
donor depletion model. In addition, for UD-SCC2 cells, 
the mean intracellular concentration of methionine, cho-
line, and betaine was significantly (p < 0.05) decreased by 
50, 90, and 85%, respectively after 168 h in methyl donor 
deplete (5%) medium compared to those cultured in control 
medium (100%) (Fig.  1b–d). After 72  h in replete condi-
tions (100% medium), the intracellular concentrations of 
methionine, choline, and betaine started to increase toward 
control cell concentrations, although these levels did not 
reach statistical significance compared to 168  h depleted 
cells (Fig. 1b–d).
Methyl donor depletion alters the phenotype of HNSCC 
cells
A reduction in methyl donor status in UD-SCC2 cells 
led to a significant (p < 0.001) dose-dependent decrease 
in cell number compared to 100% control medium over 
168  h (Fig.  2a). Similar dose-dependent findings were 
observed for UPCI-SCC72 cells (Supplementary Fig. 2B), 
although we found these cells to be less tolerant of methyl 
donor depletion, with concentrations below 20% caus-
ing cell death. In addition, UD-SCC2 cells grown in com-
plete medium (100%) displayed a cell-doubling time of 
39  h, whereas cells cultured with 10, 5, and 0% of com-
plete methyl donor concentrations displayed substan-
tially longer cell-doubling times of 86, 124, and 741  h, 
respectively (Fig.  2b). The same trend was observed for 
UPCI-SCC72 cells (Supplementary Fig.  2C). The reduc-
tion in UD-SCC2 cell-doubling time was, in part, a result 
of decreased cell proliferation. The proliferation index of 
deplete cells measured using flow cytometry was signifi-
cantly (p < 0.005) lower than that for control cells after 72 h 
and dose-dependent after 168 h (Fig. 2c). Because change 
in cell number is affected by both cell proliferation and cell 
death, we measured cell apoptosis and necrosis after 168 h 
depletion. The proportion of cells undergoing apoptosis 
increased significantly in a dose-dependent manner when 
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cultured with reducing levels of methyl donors in both UD-
SCC2 (Fig.  2d) and UPCI-SCC72 cells (Supplementary 
Fig. 2D). Approximately, 15% of UD-SCC2 cells cultured 
in methyl donor depleted conditions (5%) were apoptotic, 
whereas less than 3% of the cells cultured in medium con-
taining 100% methyl donors were apoptotic after 168  h 
(Fig. 2d). The proportion of necrotic cells was not affected 
by methyl donor depletion (Fig.  2d). UD-SCC2 cells cul-
tured in methyl donor depleted medium (5%) displayed 
visibly reduced cell motility after 72 h (Fig. 2e, f). Image 
analyses showed that cell migration was fourfold lower in 
methyl donor deplete cells compared to those cultured in 
complete medium (p < 0.001; Fig. 2f). This observed differ-
ence was due to cell migration and was not a consequence 
of cell proliferation, because cells were pre-treated with 
mitomycin C to inhibit cell division prior to the migration 
assay. The reduced capacity for cell migration and prolif-
eration was not due to metabolic shock in methyl depleted 
cells as their metabolism, as determined by MTT assay, 
was not significantly different from control cells (Supple-
mentary Fig. 3a, b).
Methyl donor depletion increases DAPK1 and PUMA 
expression and affects DAPK1 phosphorylation status 
in UD-SCC2 cells
Since methyl donor depletion caused significantly more 
apoptosis in HPV-positive UD-SCC2 cells compared 
to HPV-negative UPCI-SCC72 cells, we further exam-
ined UD-SCC2 cells for likely mechanisms of increased 
methyl-donor deplete-induced apoptosis. Gene expression 
of DAPK1 and PUMA, key enzymes involved in mediating 
apoptosis and autophagy, was increased fourfold (p < 0.05) 
and 13-fold (p < 0.01), respectively, following culture in 
methyl donor deplete medium (5%) for 168  h compared 
to expression in cells cultured in methyl donor containing 
(100%) medium (Fig. 3a, b). This change in expression was 
completely reversed when cells were cultured in replete 
Fig. 1  Validation of methyl donor depletion in UD-SCC2 cells. 
Disruption to the one carbon metabolism cycle leads to an increase 
in extracellular homocysteine and loss of intracellular methionine, 
choline, and betaine. Extracellular homocysteine concentration was 
measured by HPLC and normalised to cell number. a Concentration 
of extracellular homocysteine increased in UD-SCC2 cells following 
72 and 168  h culture in depleted (5%) methyl donor medium com-
pared to control cells (100%). The intracellular levels of b methio-
nine, c betaine, and d choline, measured by LC-MS/MS were all 
significantly decreased in UD-SCC2 cells upon methyl donor deple-
tion compared to controls (*p < 0.05) and showed signs of recovery 
after repletion in 100% methyl donor culture conditions for 72 h. n = 3 
independent experiments performed in triplicate; one-way independ-
ent ANOVA with a Bonferroni post-hoc comparison
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(100%) methyl donor medium for a further 72 h (Fig. 3a, 
b). Levels of total DAPK1 protein expression as well as the 
phosphorylated, inactive form were measured by immu-
noblotting. In support of the qPCR data, levels of total 
DAPK1 protein increased upon methyl donor depletion 
(5%) compared to cells cultured in 100% medium (Fig. 3c). 
In addition, an immunoblot band corresponding to the 
phosphorylated, inactive form of DAPK1 was observed in 
extracts derived from cells cultured in methyl donor con-
taining medium (100%), whereas phosphorylated DAPK1 
(pDAPK1) was absent in lysates from cells cultured in 
deplete conditions (5%). When the cells were returned to 
control media, the level of pDAPK1 returned to control lev-
els demonstrating the effect was reversible (Fig. 3c).
Expression of DNMT 3a and TET1 is increased 
in methyl donor deplete HPV-positive HNSCC cells
Expression of DNMT1, the enzyme responsible for main-
taining DNA methylation, was not altered in UD-SCC2 
cells depleted of methyl donors (5%) for 168  h when 
compared to cells cultured in complete (100%) medium, 
or following culture in replete medium for a further 72  h 
(Fig.  4a). However, expression of DNMT3a, the enzyme 
responsible for de novo DNA methylation, was significantly 
(p < 0.01) increased following methyl donor depletion for 
168 h and this change was reversed when these cells were 
cultured with methyl donor-containing medium, p < 0.01 
(Fig. 4b). A similar trend was also observed for expression 
Fig. 2  Effect of methyl donor 
depletion on UD-SCC2 cell 
growth, viability, and migra-
tion. a Change in cell number 
for cells cultured in media 
containing three different levels 
of methyl donor depletion 
(0, 5 and 10%) compared to 
cells grown in control media 
(100%). b Cell doubling time 
for UD-SCC2 cells cultured in 
media containing three different 
levels of methyl donor depletion 
(10, 5 and 0%) compared to 
cells grown in control media 
(100%). c Proliferation of cells 
cultured in media containing 
three different levels of methyl 
donor depletion (0, 5, and 
10%), compared to cells grown 
in control media (100%) for 
72 and 168 h. Higher prolif-
eration index indicates more 
proliferating cells and increased 
proliferation rates. d Proportion 
of cells undergoing apoptosis 
(Annexin V positive) or necro-
sis (PI positive, Annexin V 
negative) following 168 h deple-
tion (5% depletion; n = 4). e 
Cell migration into an exclusion 
zone (white dotted line on rep-
resentative images) following 
72 h depletion was compared 
to cells grown in complete 
media (100%). All cells were 
treated with mitomycin C prior 
to use in the migration assay to 
inhibit cell proliferation. f Area 
of migration quantified from 
three independent experiments 
(independent Student’s t test). 
One-way independent ANOVA 
with Bonferroni post-hoc com-
parison; *p < 0.05, **p < 0.01, 
**p < 0.005
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of DNMT3b, although this was not statistically significant 
(Fig. 4c). In addition, expression of TET1 was significantly 
(p < 0.01) increased in UD-SCC2 cells depleted of methyl 
donors (5%) for 168 h when compared to cells cultured in 
complete (100%) medium. Unlike expression of DNMT3a, 
expression of TET1 remained elevated even after 72 h cul-
ture in replete (100% methyl donor-containing) medium, 
but expression was reversed after 168 h in replete culture 
conditions (Fig. 3d).
The promoter of DAPK1 is not consistently methylated 
in HPV-positive HNSCC cells
Since increased DAPK1 gene methylation has been associ-
ated with persistent HPV infection [38] and the promoter 
region of DAPK1 has also been shown to be hypermethyl-
ated in HNSCC [18], we investigated the methylation status 
of the DAPK1 promoter in a panel of six HNSCC cell lines, 
an oral dysplastic cell line, and a basaloid squamous cell 
carcinoma cell line (all cultured in methyl donor contain-
ing medium). SiHa cervical carcinoma cells were used as 
methylated DAPK1 promoter controls. Of all the HNSCC 
and dysplastic cell lines tested, only SCC154 displayed a 
methylated DAPK1 promoter (Fig. 4e).
Discussion
There is evidence to suggest that altered folate status influ-
ences the risk of cancer and there are plausible mechanisms 
to support this [39, 40]. Studies of methyl donors other 
than folate have indicated a complex interaction between 
methyl donor availability and function, whereby deficiency 
in one methyl donor may be compensated for by another, 
to maintain a functional methyl cycle [41, 42]. However, 
very few studies have examined effects of depletion of 
more than a single methyl donor, where the opportunity 
for such compensation is minimised. In this study, we suc-
cessfully developed a model of functional methyl donor 
deficiency that was characterised by an increased concen-
tration of homocysteine in the extracellular medium and 
decreased intracellular levels of methyl donors, indicating 
disturbance to the methyl cycle [36, 37]. The time-related 
change in extracellular homocysteine was different in the 
two cell lines used. This may reflect cell-specific sensitivity 
Fig. 3  Effect of methyl donor 
depletion on DAPK1 gene 
expression and protein levels. 
Gene expression of aDAPK1 
and bPUMA in UD-SCC2 cells 
measured by qPCR relative to 
β2-microglobulin expression 
after 168 h depletion and 72 h 
repletion. c Protein expres-
sion of total DAPK1 protein 
and phosphorylated DAPK1 
(160 kDa) along with β-actin 
loading control (45 kDa) in 
UD-SCC2 cells. In a–c, gene 
and protein expression was 
measured in UD-SCC2 cells fol-
lowing methyl donor depletion 
for 168 h with medium contain-
ing 5% methyl donors (deplete) 
followed by a further 72 h 
culture in medium containing 
100% methyl donors (replete). 
Control cells were continuously 
cultured in 100% methyl donor 
containing medium alongside 
deplete and replete cells
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to methyl donor depletion, including differential up-regu-
lation of folate receptors and/or homocysteine metabolism 
[43, 44].
Cancer cell motility is important for tumour cell inva-
sion during HNSCC progression and subsequently leads 
to the development of local or distant site metastases. Our 
data demonstrate for the first time that HNSCC cell migra-
tion is significantly impaired in methyl donor depleted con-
ditions. Moreover, the cellular response is unlikely to be 
due to metabolic shock as the metabolic status of deplete 
and control cells was similar. This is an important finding 
as increased cell migration has been associated with poor 
prognosis in HNSCC [45] and the ability to immobilise 
cancer cells is an important target for cancer drug devel-
opment. There has been relatively little research into the 
effects of methyl donor depletion on tumour cell migra-
tion and findings suggest that effects may be cell specific. 
Human HCT116 colon carcinoma cells showed increased 
migration in folate-deplete conditions [46], whereas Grazi-
osi et  al. reported reduced cell migration in methionine-
depleted gastric cancer cells [47]. The effects on migration 
may be mediated by epigenetic alterations in the expression 
of genes important for cell locomotion. The actin cytoskel-
eton plays a central role in cell movement and studies on 
the effects of methyl donor depletion in various cell types 
suggest that genes associated with the regulation of the 
actin cytoskeleton are invariably down regulated. Duthie 
et al. reported reduced expression of proteins important for 
cytoskeleton organization in folate-depleted human colono-
cytes [8], whilst Jhaveri et  al. showed down-regulation of 
Fig. 4  Effect of methyl donor depletion and repletion on DNMT and 
TET1 expression. Gene expression of DNMT1 (a), DNMT3a (b), and 
DNMT3b (c) and d TET1 relative to β2 M expression was measured 
using qPCR in UD-SCC2 cells. Expression was measured following 
methyl donor depletion for 168 h with medium containing 5% methyl 
donors (deplete) followed by a further 72 h culture in medium con-
taining 100% methyl donors (and 168 h for TET1) (replete). Control 
cells were continuously cultured in 100% methyl donor containing 
medium alongside deplete and replete cells. n = 6, independent Stu-
dent’s t test, **p < 0.01. e Presence of methylated DAPK1 promoter 
in a panel of HNSCC cell lines as measured by qMSP; the cervical 
cell lines SiHa were used as controls. Table shows cells positive for 
DAPK1 methylation (+, Ct values <35) and cells negative for methyl-
ated DAPK1 (−, Ct values >35). All cell lines tested were positive for 
β-actin (mean Ct value 25 ± 0.47)
Eur J Nutr 
1 3
cytoskeleton 14 in folate-depleted human KB (HeLa) cells 
[48].
The observed reduction in cell proliferation in methyl-
donor deplete UD-SCC2 cells could, in part, be explained 
by a shortage of purine and pyrimidines that are essential 
for DNA production, as methyl donors are required for the 
synthesis of these molecules. An alternative explanation 
may be that methyl donor-depleted cells are arrested at G1 
in the cell cycle, as has previously been reported in human 
and murine B cells with reduced levels of methionine and 
SAM [49]. The effect on cell proliferation observed in this 
study was dose-dependent and the rate of cell proliferation 
was restored following repletion. The decrease in cell pro-
liferation rate detected in methyl donor-deficient cultures 
did not account entirely for the reduction in cell number 
observed. Cell death, through apoptosis, also increased in 
the methyl donor depleted conditions, while cell necrosis 
remained unchanged.
The role that folate plays in DNA synthesis and cell 
division is well understood and this is the basis for the 
use of anti-folate drugs in cancer treatment. A decrease in 
methyl donor availability is expected to lead to a fall in cell 
proliferation and this is what we observed. Evidence link-
ing folate status with apoptosis is limited and inconsistent 
[50–52]. An increase in apoptosis is understood to have 
beneficial effects in cancer and a low level of apoptosis in 
HNSCC is associated with poor prognosis [53]. Low avail-
ability of methyl donors, in particular folate, may lead to 
reduced DNA synthesis and thus inhibit tumour cell prolif-
eration of established tumours.
DAPK1 and PUMA are pro-apoptotic genes known to 
be up-regulated when cells encounter stress [54, 55]. We 
hypothesised that activation of pro-apoptotic genes medi-
ates the increase in apoptosis observed in methyl donor 
depleted cells. DAPK1 and PUMA mRNA levels signifi-
cantly increased following methyl donor depletion and, in 
the case of DAPK1, this was associated with an increase 
in protein levels as well, a response that was reversed upon 
methyl donor repletion. Interestingly, cells that were methyl 
donor deficient also displayed reduced levels of phospho-
rylated DAPK1, the inactive form of the protein, compared 
to cells cultured in complete media. These data suggest that 
upon prolonged methyl donor depletion, cells respond by 
not only increasing the gene expression of DAPK1 but also 
by increasing the active, non-phosphorylated form of the 
protein that then drives the pro-apoptotic pathway leading 
to the programmed cell death of HNSCC cells.
A functionally impaired methyl cycle was associated 
with effects on the expression of DNMTs and TET1. The 
expression of DNMT1, the DNMT involved in maintain-
ing DNA methylation status following cell division [19], 
was not influenced by a reduction in methyl donor status 
in UD-SCC2 cells. Reports of effects of folate depletion 
on DNMT1 expression in cultured cells are inconsistent; 
Stempak et  al., [56] reported a down-regulation in mouse 
fibroblasts and human colon cancer cells, whilst Hayashi 
et al. [32] observed an up-regulation in response to folate 
depletion of the same human colon cancer cells. In con-
trast to DNMT1, expression of DNMT3a was increased in 
methyl donor deplete UD-SCC2 cells and this effect was 
reversed upon methyl donor repletion. A similar direc-
tion of change was seen for DNMT3b, although the effect 
was not statistically significant. Others have reported an 
increase in the expression of DNMT3a in response to 
methyl donor depletion in animal models and the rela-
tive resistance of DNMT3b to methyl donor depletion has 
also been documented in these studies [57, 58]. However, 
colon cancer cells depleted of folate alone are reported 
to show a decrease in DNMT3a [32, 56], and Poomipark 
et  al. reported a decrease in DNMT3a and DNMT3b in a 
folate and methionine-depleted cervical cancer cell line 
C4II [22], adding to the evident inconsistency of response 
to single or multiple methyl donor depletion in different 
experimental systems. The fact that we were able to dem-
onstrate reversibility of the effect on DNMT3a expression 
is a strong indicator of the causal relationship between 
methyl donor availability and DNMT3a expression in 
HNSCC cells. It is plausible that in methyl donor deplete 
HNSCC cells, expression of DNMT3a and TET1 (respon-
sible for DNA demethylation) is increased as an adaptive 
response, to scavenge cellular sources of methyl groups and 
maintain epigenetic control of gene transcription. Deletion 
of DNMT3a has been shown to promote lung tumour pro-
gression [59] and expression has been shown to be higher 
in leukaemia compared with control cells [60]. Sun et  al. 
recently showed that inhibition of DNMT3a in cervical can-
cer cells induced apoptosis, suggesting a cancer promoting 
effect of DNMT3a [61]. In our study, increased expression 
of DNMT3a and TET1 was associated with increased apop-
tosis; whether these responses to methyl donor depletion 
are causally linked is not clear.
Methylation of both host and viral DNA is thought 
to be important in HPV-positive cancers, with distinct 
methylation patterns observed in HPV-positive and nega-
tive disease [62]. It has previously been shown that the 
DAPK1 promoter is hyper-methylated in oral cancer cells 
and the prevalence of DAPK1 methylation in oral can-
cer ranges from 7 to 68% [18]. This led us to hypothesise 
that in methyl donor deplete conditions, the lack of read-
ily available methyl groups would result in loss of meth-
ylation within the DAPK1 promoter, leading to increased 
DAPK1 gene expression, increased protein production and 
activity, and, therefore, increased apoptosis. The previous 
studies have shown variations in gene methylation patterns 
following folate depletion in  vitro depending on the cell 
type and gene of interest [39]. However, we found that the 
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DAPK1 promoter was not methylated in UD-SCC2 HPV-
positive cells or in several other HNSCC/dysplastic (HPV-
negative) cell lines. This was not due to a lack of specific-
ity of the PCR primers used as SiHa cervical carcinoma 
cells displayed methylated DAPK1 as previously described 
[63]. These data suggest that other mechanisms regulating 
DAPK1 gene expression and activation are at play in these 
cells or that the DAPK1 gene is under epigenetic control at 
other sites within the promoter region that were not covered 
by our primer sequences.
The evidence presented from this study indicates that 
methyl donor depletion of HNSCC cell lines results in 
a less aggressive cancer cell phenotype. Cancer cells 
which display reduced proliferation, increased apoptosis, 
and decreased migration are highly likely to produce less 
aggressive tumours in vivo. While low folate consumption 
is considered to be a risk factor for cancer at various sites, 
this may not be true for established cancers or in cells that 
contain microscopic neoplastic foci where folate could pro-
mote rather than prevent carcinogenesis through the provi-
sion of nucleotide precursors required for growth of rapidly 
dividing cancer cells [64, 65]. Indeed, there is increasing 
evidence from studies in animals and humans to suggest 
that whilst adequate folate status may be protective against 
cancer initiation, folate deficiency can slow cancer growth, 
whilst high intakes may enhance growth of certain cancers, 
including colorectal, breast, and prostate cancer [64–66]. 
Recent evidence extends this observation to other nutrients 
involved in the methyl cycle [67].
This study has demonstrated that depleting HNSCC 
cells of methyl donors has beneficial effects in terms of the 
cancer phenotype and provides mechanistic data to support 
evidence suggesting that high intakes of methyl donors may 
have adverse effects in established cancers or where pre-
cancerous lesions exist.
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